Glenmark Pharmaceuticals Limited reported earnings results for the third quarter and nine months ended December 31, 2023. For the third quarter, the company reported sales was INR 24,602.9 million compared to INR 30,627.5 million a year ago. Revenue was INR 25,521.12 million compared to INR 31,707.4 million a year ago. Net loss was INR 3,513.74 million compared to net income of INR 2,725.79 million a year ago. Basic loss per share from continuing operations was INR 16.66 compared to basic earnings per share from continuing operations of INR 5.94 a year ago. Diluted loss per share from continuing operations was INR 16.66 compared to diluted earnings per share from continuing operations of INR 5.94 a year ago. Basic loss per share was INR 12.45 compared to basic earnings per share of INR 9.66 a year ago. Diluted loss per share was INR 12.45 compared to diluted earnings per share of INR 9.66 a year ago.
For the nine months, sales was INR 86,194.5 million compared to INR 84,735.73 million a year ago. Revenue was INR 88,169.75 million compared to INR 89,140.47 million a year ago. Net loss was INR 2,833.86 million compared to net income of INR 7,255.47 million a year ago. Basic loss per share from continuing operations was INR 23.26 compared to basic earnings per share from continuing operations of INR 14.35 a year ago. Diluted loss per share from continuing operations was INR 23.26 compared to diluted earnings per share from continuing operations of INR 14.35 a year ago. Basic loss per share was INR 10.04 compared to basic earnings per share of INR 25.71 a year ago. Diluted loss per share was INR 10.04 compared to diluted earnings per share of INR 25.71 a year ago.